Range Cancer Therapeutics ETF (CNCR) Short Interest Ratio & Short Volume → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial Media Range Cancer Therapeutics ETF Short Interest DataCurrent Short Volume2,900 sharesPrevious Short Volume13,900 sharesChange Vs. Previous Month-79.14%Dollar Volume Sold Short$42,804.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares1,180,000 sharesPercentage of Shares Shorted0.25%Today's Trading Volume4,718 sharesAverage Trading Volume6,668 sharesToday's Volume Vs. Average71% Short Selling Range Cancer Therapeutics ETF ? Sign up to receive the latest short interest report for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCNCR Short Interest Over TimeCNCR Days to Cover Over TimeCNCR Percentage of Float Shorted Over Time Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest Range Cancer Therapeutics ETF Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,900 shares $42,804.00 -79.1%N/A0.1 $14.76 4/15/202413,900 shares $208,639.00 -50.2%N/A0.4 $15.01 3/31/202427,900 shares $463,698.00 -59.2%N/A0.8 $16.62 3/15/202468,300 shares $1.11 million +73.4%N/A2.1 $16.26 2/29/202439,400 shares $680,438.00 +47.0%N/A2.6 $17.27 2/15/202426,800 shares $429,738.00 +538.1%N/A2.9 $16.04 Get the Latest News and Ratings for CNCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. 1/31/20244,200 shares $59,472.00 No ChangeN/A0.8 $14.16 5/15/2023100 shares $1,374.00 -92.9%N/A0 $13.74 4/30/20231,400 shares $17,707.90 -44.0%N/A0.2 $12.65 4/15/20232,500 shares $31,025.00 +257.1%N/A0.4 $12.41 3/31/2023700 shares $8,393.00 +16.7%N/A0.1 $11.99 3/15/2023600 shares $7,494.00 -78.6%N/A0.2 $12.49 2/28/20232,800 shares $37,660.00 -47.2%N/A0.8 $13.45 2/15/20235,300 shares $75,366.00 -38.4%N/A1.5 $14.22 1/31/20238,600 shares $127,710.00 -4.4%N/A2.5 $14.85 1/15/20239,000 shares $132,750.00 +5.9%N/A1.4 $14.75 12/30/20228,500 shares $116,705.00 -35.6%N/A1.3 $13.73 12/15/202213,200 shares $200,376.00 +12.8%N/A1.4 $15.18 11/30/202211,700 shares $174,447.00 +9.4%N/A1.3 $14.91 11/15/202210,700 shares $165,743.00 -23.0%N/A1.2 $15.49 10/31/202213,900 shares $208,500.00 +0.7%N/A1.5 $15.00 10/15/202213,800 shares $201,894.00 No ChangeN/A2.1 $14.63 9/30/202212,700 shares $183,134.00 -21.1%N/A1.7 $14.42 9/15/202216,100 shares $260,820.00 +3.9%N/A3 $16.20 8/31/202215,500 shares $240,405.00 -15.8%N/A2.2 $15.51 8/15/202218,400 shares $330,832.00 +13.6%N/A2.5 $17.98 7/31/202216,200 shares $259,200.00 -12.0%N/A2.1 $16.00 7/15/202218,400 shares $304,704.00 -27.0%N/A2.4 $16.56 6/30/202225,200 shares $382,788.00 -2.0%N/A3.8 $15.19 6/15/202225,700 shares $345,022.50 +26.0%N/A3.7 $13.43 5/31/202220,400 shares $283,941.48 +23.6%N/A3.9 $13.92 5/15/202216,500 shares $236,445.00 +17.0%N/A3.4 $14.33 4/30/202214,100 shares $218,225.70 -6.0%N/A3.1 $15.48 4/15/202215,000 shares $264,150.00 -8.5%N/A2.1 $17.61 3/31/202216,400 shares $297,332.00 -13.7%N/A1.9 $18.13 3/15/202219,000 shares $311,790.00 +36.7%N/A2.3 $16.41 2/28/202213,900 shares $255,760.00 -30.5%N/A1.6 $18.40 2/15/202220,000 shares $372,020.00 +48.2%N/A2.2 $18.60 1/31/202213,500 shares $247,847.85 +5.5%N/A1.5 $18.36 1/15/202212,800 shares $261,120.00 +1,728.6%N/A1.9 $20.40The Department of Defense Has a New Drone Contractor (Ad)The Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest CNCR Short Interest - Frequently Asked Questions What is Range Cancer Therapeutics ETF's current short interest? Short interest is the volume of Range Cancer Therapeutics ETF shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,900 shares of CNCR short. Learn More on Range Cancer Therapeutics ETF's current short interest. Is Range Cancer Therapeutics ETF's short interest increasing or decreasing? Range Cancer Therapeutics ETF saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 2,900 shares, a decrease of 79.1% from the previous total of 13,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Range Cancer Therapeutics ETF's short interest compare to its competitors? Here is how the short interest of companies compare to Range Cancer Therapeutics ETF: First Trust Nasdaq Pharmaceuticals ETF (0.13%), JPMorgan Healthcare Leaders ETF (0.08%), Invesco Nasdaq Biotechnology ETF (1.30%), ProShares UltraShort Nasdaq Biotechnology (8.82%), Principal Healthcare Innovators ETF (0.36%), ProShares Ultra Nasdaq Biotechnology (0.99%), Invesco S&P SmallCap Health Care ETF (0.03%), VanEck Biotech ETF (0.08%), VanEck Pharmaceutical ETF (24.24%), and iShares Biotechnology ETF (16.44%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Range Cancer Therapeutics ETF stock? Short selling CNCR is an investing strategy that aims to generate trading profit from Range Cancer Therapeutics ETF as its price is falling. CNCR shares are trading down $0.38 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Range Cancer Therapeutics ETF? A short squeeze for Range Cancer Therapeutics ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCR, which in turn drives the price of the stock up even further. How often is Range Cancer Therapeutics ETF's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCR, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: First Trust Nasdaq Pharmaceuticals ETF Short Interest Data JPMorgan Healthcare Leaders ETF Short Interest Data Invesco Nasdaq Biotechnology ETF Short Interest Data ProShares UltraShort Nasdaq Biotechnology Short Interest Data Principal Healthcare Innovators ETF Short Interest Data ProShares Ultra Nasdaq Biotechnology Short Interest Data Invesco S&P SmallCap Health Care ETF Short Interest Data VanEck Biotech ETF Short Interest Data VanEck Pharmaceutical ETF Short Interest Data iShares Biotechnology ETF Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CNCR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBill Clinton Backing Biden Replacement???The Freeport SocietyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals